ArticleFrontiers in immunology2026
Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monoclonal antibodies targeting CD20-expressing B cells constitute effective therapies for people with multiple sclerosis (pwMS) and can be administered intravenously (i.v.) or subcutaneously (s.c.). However, little is known about the differences in immunomodulatory effects of distinct B-cell depletion therapies. Methods: We performed detailed characterizations of the immune cell composition in blood samples of pwMS treated with either i.v. [ocrelizumab (Ocre); Results: Both anti-CD20 mAbs resulted in a depletion of CD19 Discussion: Our data add to the knowledge on distinct antibody-specific properties and differential effects of s.c. versus i.v. administered B-cell depletion in pwMS. We identified a higher percentage of memory B cells in s.c. Ocre and Ofa B cell-depleted pwMS and pwMS who switched their anti-CD20 therapy from i.v. Ocre to s.c. Ofa injection. Further analysis will be needed to investigate how these observations link to safety and efficacy profiles of the different anti-CD20 therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.